Browse the corpus

©2013 UpToDate ® Print Email Use of bisphosphonates in women treated with AIs Trial N F/U, mo Treatment Mean percentage difference in BMD between groups Fractures, percent LS Hip Z-FAST 602 12 LET + ZA/D-ZA 4.4 [p<0.0001] 3.3 [p<0.0001] 1.0 versus 0.7 36 6.7 [p<0.001] 5.2 [p<0.001] 5.6 versus 6.3 61 8.9 [p<0.001] 6.7 [p<0.001] 9.3 versus 11.0 ZO-FAST 1065 12 LET + ZA/D-ZA 5.7 [p<0.0001] 3.6 [p<0.0001] 36 9.3 [p<0.0001] 5.4 [p<0.0001] 5.0 versus 6.0 SABRE 234 24 ANA + R/Placebo 4.0 [p<0.0001] 2.9 [p<0.0001] NA LET: letrozole; F/U: follow-up; BMD: bone mineral density; ZA: zoledronic acid; D: delayed; ANA: anastrazole; R: risedronate. Modified with data from:  1. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28:967. 2. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvent letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188. 3. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192. Reproduced with permission from: Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright © 2008 Adis Data Information BV.